切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (02) : 69 -73. doi: 10.3877/cma.j.issn.2095-3216.2015.02.003

所属专题: 文献

专家论坛

尿酸性肾病的中西医结合治疗进展
汪年松1,(), 桂定坤1   
  1. 1. 200233 上海交通大学附属第六人民医院肾脏内科
  • 出版日期:2015-04-28
  • 通信作者: 汪年松

Treatment of uric acid nephropathy with integrated traditional Chinese and western medicine

Niansong Wang1,()   

  1. 1. Department of Nephrology, Sixth People′s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, China
  • Published:2015-04-28
  • Corresponding author: Niansong Wang
  • About author:
    Corresponding author: Wang Niansong, Email:
引用本文:

汪年松, 桂定坤. 尿酸性肾病的中西医结合治疗进展[J/OL]. 中华肾病研究电子杂志, 2015, 04(02): 69-73.

Niansong Wang. Treatment of uric acid nephropathy with integrated traditional Chinese and western medicine[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(02): 69-73.

随着经济和社会的发展及人民生活水平的提高,我国高尿酸血症(HUA)的患病率逐年升高。HUA可造成多脏器损害。尿酸性肾病是尿酸结晶沉积于肾脏而引起的病变。目前,中西医结合治疗已应用于尿酸性肾病。西医通过抑制尿酸合成,促进尿酸排泄,抑制炎症等途径缓解高尿酸血症。尿酸酶类药物是近年来降低尿酸的一类新药,包括重组黄曲霉菌尿酸氧化酶,聚乙二醇化重组尿酸氧化酶。中药单剂鸡矢藤提取物、金刚藤提取物、槲皮素和芦丁提取物在减轻高尿酸血症、保护肾脏方面有积极作用;中药复方中的二妙丸、四妙汤以及四物汤联合二妙散可抑制高尿酸血症,改善肾功能。因此,尿酸性肾病应重视中西医结合治疗。

With the development of economy and society, and the improvement of people′s living standard, the prevalence of hyperuricemia increases year by year in China, which can cause multiple organ damage. Uric acid nephropathy is a disease due to deposit of urate crystals in the kidney. At present, integrated traditional Chinese medicine and western medicine have been used in the treatment of uric acid nephropathy. In western medicine, hyperuricemia can be ameliorated by inhibiting uric acid synthesis, promoting excretion of uric acid, and suppressing inflammation, and so on. Uricase is a new class of drugs to reduce uric acid in recent years, including rasburicase and PEG-uricase. Single agents of traditional Chinese medicine, such as iridiod glycosides from paederia scandens, ethanol extract of rhizoma smilasic chinae, quercetin, and rutin, have positive roles in relieving hyperuricemia and protecting kidney. Compounds of traditional Chinese medicine, including Ermiao pill, Simiao decoction, and Siwu decoction combined with Ermiao powder can inhibit the hyperuricemia so as to improve renal function. Therefore, integrated traditional Chinese medicine and western medicine are important in the treatment of uric acid nephropathy.

[1]
Moran ME. Uric acid stone disease [J]. Front Biosci, 2003, 1(8): S1339-S1355.
[2]
李迎巧,高建东. 尿酸性肾病的中医药防治研究进展[J]. 中国中西医结合肾病杂志,2014,15(3):270-272.
[3]
Ben-Dov IZ, Kark JD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study [J]. Nephrol Dial Transplant, 2011, 26(8): 2558-2566.
[4]
中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.
[5]
刘慧. 新型降尿酸药非布索坦的临床研究进展[J]. 中国医药科学,2013,3(13):37-39.
[6]
姚远兵,王玲,夏悦,等. 新型抗痛风药物非布索坦概述[J]. 中国药师,2012,15(6):886-889.
[7]
王丽英,赵燕,郑毅,等. 随机双盲三模拟对照多中心临床研究非布索坦降低痛风患者高尿酸水平的疗效和安全性[J/CD]. 中华临床医师杂志(电子版), 2013,7(7):2798-2803.
[8]
傅毅. 高尿酸血症治疗药拉布立酶(rasburicase)[J]. 国外医药(合成药、生化药、制剂分册),2002,23(6):383-384.
[9]
Pui CH. Rasburicase: a potent uricolytic agent [J]. Expert Opin Pharmacother, 2002, 3(4): 433-442.
[10]
王成君. 新型抗痛风药物-Pegloticase[J]. 医药导报,2012,31(9):1188-1189.
[11]
刘霞,祁兢晶. 秋水仙碱脂质体凝胶对痛风模型动物的抗炎作用[J]. 广东医学,2011,32(23):3038-3040.
[12]
Ararat E, Brozovich FV. Losartan decreases p42/44 MAPK signaling and preserves LZ+MYPT 1 expression [J]. PLoS One, 2009, 4(4):e5144.
[13]
肖祖容,苏军霞,李建华,等.尿酸性肾病的治疗进展[J].甘肃科技纵横,2011,40(4):191-193.
[14]
Uchida S, Takahashi M, Sugawara M, et al. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE Study) [J]. J Clin Hypertens (Greenwich), 2014, 16(10): 746-753.
[15]
金辉,庞明群,苏宇,等. 鸡矢藤环烯醚萜苷对尿酸性肾病大鼠的防治作用[J]. 安徽医科大学学报,2011,46(10):1026-1028.
[16]
Hou SX, Zhu WJ, Pang MQ, et al. Protective effect of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats induced by yeast and potassium oxonate [J]. Food Chem Toxicol, 2014, 64: 57-64.
[17]
中华人民共和国药典委员会.中国药典(一部) [M].北京:化学工业出版社,2005:216-217.
[18]
邓家刚,陈壮. 金刚藤活性成分与药效学及临床应用研究[J]. 河南中医学院学报,2005,20(3):23-24.
[19]
Chen L, Yin H, Lan Z, et al. Anti-hyperuricemic and nephroprotective effects of Smilax china L [J]. J Ethnopharmacol, 2011, 135(2): 399-405.
[20]
Wang C, Pan Y, Zhang QY, et al. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation [J]. PloS One, 2012, 7(6): e38285.
[21]
Zhu JX, Wang Y, Kong LD, et al. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver [J]. J Ethnopharmacol, 2004, 93(1): 133-140.
[22]
Kong LD, Yang C, Ge F, et al. A Chinese herbal medicine Ermiao wan reduces serum uric acid level and inhibits liver xanthine dehydrogenase and xanthine oxidase in mice [J]. J Ethnopharmacol, 2004, 93(2-3): 325-330.
[23]
Hu QH, Jiao RQ, Wang X, et al. Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice [J]. J Ethnopharmacol, 2010, 128(3): 685-692.
[24]
Hua J, Huang P, Zhu CM, et al. Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice [J]. J Ethnopharmacol, 2012, 142(1): 248-252.
[25]
蒋茜,郭永平,王毅兴,等. 四物汤合二妙散降低高尿酸血症大鼠血尿酸水平的实验研究[J]. 中国中西医结合肾病杂志,2012,13(4):336-338.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[6] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[7] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[8] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[9] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?